NCT00189241

A Study to Evaluate Effectiveness of Imiquimod 5% Cream in Superficial Basal Cell Carcinoma

An Open-Label Study to Evaluate the Safety and Long-Term Clinical Efficacy of Imiquimod 5% Cream Applied Once Daily 5 Days Per Week for 6 Weeks in the Treatment of Superficial Basal Cell Carcinoma

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 160 (planned)
• Sponsor: MEDA Pharma GmbH & Co. KG · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the long-term sustained clearance rate of superficial basal cell carcinoma during a 5 year period following treatment with imiquimod

Conditions

• Basal Cell Carcinoma

Interventions

Type	Name	Description
DRUG	imiquimod

Timeline

• Start date: 2001-02-01
• Primary completion: 2007-02-01
• Completion: 2007-02-01
• First posted: 2005-09-19
• Last updated: 2022-02-07

Locations

1 site across 1 country: Germany